Corporate Presentation

Nucleic Acid Therapeutics Come of Age Over $42B Total Market Cap Dicerna™ ProQR arrowhead pharmaceuticals Small Molecules WAVE™ LIFE SCIENCES neubase CHECKMATE IONIS PHARMACEUTICALS AVIDITY BIOSCIENCES PHARMACEUTICALS STOKE THERAPEUTICS THERAPEUTICS IDERA Protein-based Antibodies 11 Approved drugs and Engineered Cellular Therapies >40 Drugs in late stage clinical development $2.9B Drug Revenues in 2019 SPINRAZA (nusinersen) 12mg/5 mL EXONDYS 51 (eteplirsen) Injection injection onpattro (patisiran) i complexnjection 10mg/5mL KYNAMRO (mipomersen sodium) injection 200mg/ml DEFITELIO (defibotide sodium Immuno-oncology CAR-T VYONDYS 53 (golodirsen) Injection OXLUMO™ (lumasiran)/5ml GIVLAARIⓇ (givosiran) injection for subcutaneous use 189 mg/mL injection Tegsedi (inotersen) injection VILTEPSO waylivra (volanesorsen) injection 285 mg/1.5 mL Nucleic Acid Therapeutics exicure | 7

View entire presentation